: iStockAnalyst.com Symbols Feed

EXACT Sciences (NASDAQ: EXAS): Patience Required For Long-Term Upside

Thu, 05 Nov 2009 01:21:28 GMT

On 11/3/09, EXACT Sciences (NASDAQ: EXAS) reported its 3Q09 results and held a conference call to outline the Company's progress and timeline for the development of a stool DNA based test kit for the early diagnosis and prevention of colorectal cancer (CRC). EXAS reported total revenue of $1.3 million (which primarily reflects non-cash recognition of Genzyme deal earlier this year), a net loss of $1 million, operating expenses of $2.3 million, and ended the quarter with cash / equivalents of $26.9 million.[More...]

BioMed News Bytes: BSD Medical, Provectus, Incyte, OncoMethylome

Tue, 22 Sep 2009 16:37:17 GMT

On 9/21/09, Provectus Pharma (OTC: PVCT.OB) ($0.96, +1%, above-average volume on 21-Sep) announced that it completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma. The primary objective of the Phase 2 study is to investigate the effectiveness of intralesional (IL) PV-10[More...]

EXACT Sciences: Smaller Phase 3 Study Will Save Time, Money

Sat, 15 Aug 2009 19:42:24 GMT

The stock research section of BioMedReports.com has been updated on 8/14/09 to reflect new developments following the 2Q09 conference call and business update for EXACT Sciences (NASDAQ:EXAS) as the Company prepares for a Phase 3 study next year to obtain FDA marketing clearance for its next-generation stool DNA (sDNA) screening test (V3) for colorectal cancer (CRC) and pre-cancers. The following is a summary of the highlights, projections, and expected milestones from my updated report for EXAS (...)[More...]

New Indexes To Track Healthcare Trends And More

Wed, 05 Aug 2009 15:34:05 GMT

Below are links and descriptions for 23 new stock indexes I have created, revised, and tracked over the past few years which are now featured at a new website called Investars YOU. The new site includes automated index tracking, allows investors to create custom stock portfolios based on their individual preferences, and now features free access to all of the component stocks in each of my indexes. Some of the top performing stocks from my healthcare indexes on a year-to-date basis (...)[More...]

EXACT Sciences (NASDAQ:EXAS): Back On Track, Report Available

Wed, 15 Jul 2009 13:13:00 GMT

EXACT Sciences (NASDAQ:EXAS) provides a timely case study on the current debate over healthcare reform in the U.S. Our current "sick-care" system focuses on the treatment of disease rather than preventative medicine initiatives through investments in wellness programs and improved diagnostic screening tests - particularly in the area of cancer screening since this represents a fast-growing, costly disease. The Company's next-generation screening test (V3) for colorectal cancer (CRC) (...)[More...]

Sequenom (NasdaqGM: SQNM) Splattered, EXACT Sciences (NasdaqCM: EXAS) On The Rise

Wed, 06 May 2009 12:11:06 GMT

With Sequenom (SQNM) losing about three-quarters of its market value in pre-market trading to around 3 bucks per share; EXACT Sciences (EXAS) is poised to continue its comeback from penny stock levels late last year and has a chance to close the year at a[More...]

Sequenom (NASDAQ:SQNM) Splattered, EXACT Sciences (NASDAQ:EXAS) On The Rise

Thu, 30 Apr 2009 16:33:17 GMT

With Sequenom (NASDAQ:SQNM) losing about three-quarters of its market value in pre-market trading to around 3 bucks per share; EXACT Sciences (NASDAQ:EXAS) is poised to continue its comeback from penny stock levels late last year and has a chance to close the year at a higher market value than its molecular diagnostics rival. SQNM launched a hostile, all-stock tender offer for EXAS earlier this year for $1.50 per share (which would now be valued at less than 40 cents), but EXACT reject (...)[More...]

Cell Therapeutics: Down, But Not Out

Mon, 02 Feb 2009 19:40:00 GMT

Cell Therapeutics (CTIC) is a micro-cap cancer biotech which is down substantially in the past year in terms of stock price and market value, but not out after recently establishing a joint venture with Spectrum Pharma (SPPI) to market Zevalin, the potential for two FDA approvals this year (one new product, one label expansion), the potential for EMEA approval of Opaxio in the E.U., and a goal to become cash flow break-even by year-end. A World Health Organization report released late last year estimates that cancer will overtake heart disease as the top cause of death in the world by 2010, which is part of an overall trend that predicts global cancer cases and deaths will more than double by 2030. The report predicts 27 million new cases of cancer will occur in 2030, which is a sharp[More...]

Beyond Stem Cells: Healthcare Hot Spots

Mon, 26 Jan 2009 18:09:00 GMT

With the surprise announcement last week by Geron (GERN) that the FDA would allow human clinical trials for embryonic stem cells, all companies in the underlying ETF Innovators Index to track the space are screaming higher again today – led by the company with the biggest gains over the past year, StemCells (STEM). Below are three additional areas and associated companies for investors to consider in the search of the next hot spots in the healthcare sector, including a focus on small/mid-cap companies which have the added potential to be acquired as part of renewed M&A in the sector this year. Molecular Diagnostics EXACT Sciences (EXAS) has rejected the hostile $1.50 all-stock offer from[More...]

New Preventive Medicine Index

Sun, 25 Jan 2009 18:49:00 GMT

One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies[More...]

Biotech Company Raises Venture Capital, Will Move to Madison

Thu, 13 Aug 2009 07:51:00 GMT

Aug. 13--Flex Biomedical Inc., a privately held company developing treatments for orthopedic diseases, said it has raised $985,000 in Wisconsin, including a $150,000 loan from the state's Technology Venture Fund, and will move its operations to Madison from Boston.
Three of the state's early-stage investment groups -- Wisconsin Investment Partners in Madison, NEW Capital Fund in Appleton and Marquette University Golden Angels Network in Milwaukee -- have invested in the company.
Flex Biomedical, which employs three people, plans to begin clinical trials late next year or in early 2011 on a synthetic polymer to treat osteoarthritis, said Sal Braico, the company's chief executive, who has moved to Madison.

[More...]

Exact Sciences Reports Second-Quarter 2009 Financial Results

Wed, 12 Aug 2009 11:50:00 GMT

Exact Sciences Corp. (Nasdaq: EXAS) today announced its financial results for the second quarter ended June 30, 2009.
Total revenues increased due to the quarterly non-cash allocation that resulted from the company's January 2009 intellectual property transaction with Genzyme Corp. Total revenues for the first six months of 2009 were $2.3 million, compared to total revenues of ($95,000) for the same period of 2008.
Exact's net loss for the six-month period ended June 30, 2009, was ($6.2) million, or ($0.21) a share, compared to ($4.6) million, or ($0.17) a share, for the same period of 2008.

[More...]

Exact Sciences Announces Appointment of Diagnostics Veteran Graham Lidgard as Chief Scientific Officer

Mon, 03 Aug 2009 20:17:00 GMT

Exact Sciences Corp. (Nasdaq: EXAS) today announced the appointment of Graham P. Lidgard, Ph.D., as the company’s chief scientific officer. Dr. Lidgard, 60, brings more than three decades of clinical diagnostics experience to Exact. His past work includes molecular and immunoassay diagnostic product development, clinical trial preparation and execution, and preparation of successful pre-market approval, or PMA, and 510(k) submissions to the U.S. Food and Drug Administration.[More...]

Exact Sciences to Host Second-Quarter 2009 Conference Call

Mon, 27 Jul 2009 15:28:00 GMT

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a conference call and question-and-answer session on Aug. 12, 2009, at 10 a.m. ET, to discuss the company's second-quarter 2009 financial results.[More...]

Exact Sciences to Webcast Shareholder Meeting Presentation

Thu, 09 Jul 2009 13:08:00 GMT

Exact Sciences Corp. (Nasdaq:EXAS) today announced that the corporate presentation at its annual meeting of shareholders will be webcast live on Friday, July 17, at approximately 10 a.m. EDT. Live audio of the presentation also will be available by telephone.[More...]

Exact Sciences Closes $8.2-Million Private Placement, Enters Into Licensing and Collaboration Agreement

Thu, 11 Jun 2009 21:43:00 GMT

Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into a collaboration and license agreement with Mayo Clinic. Exact also announced that it has closed an $8.2-million private placement of 4.3 million shares of its common stock.[More...]

Exact Sciences Reports First-Quarter Financial Results

Tue, 05 May 2009 11:13:00 GMT

Exact Sciences Corp. (Nasdaq:EXAS) today announced its financial results for the quarter ended March 31, 2009.[More...]

Connelly, Napier Appointed to Exact Sciences’ Board of Directors

Mon, 27 Apr 2009 20:11:00 GMT

Exact Sciences Corp. (Nasdaq: EXAS) today announced that James P. Connelly and Katherine S. Napier have joined the company’s board of directors.[More...]

Exact Sciences to Host First-Quarter 2009 Conference Call

Tue, 14 Apr 2009 13:13:00 GMT

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a conference call and question-and-answer session on May 5, 2009, at 10 a.m. ET, to discuss the company's first-quarter 2009 financial results.[More...]

Exact Sciences Announces Fourth-Quarter and Year-End 2008 Financial Results

Mon, 30 Mar 2009 19:59:00 GMT

EXACT Sciences Corp. (NASDAQ: EXAS) today announced its financial results for the fourth quarter and year ended Dec. 31, 2008.[More...]

EXACT Sciences Announces New Management Team

Wed, 18 Mar 2009 19:57:00 GMT

EXACT Sciences Corp. (NASDAQ: EXAS) today announced that the company’s board of directors has appointed Kevin T. Conroy as president and chief executive, and Maneesh K. Arora as senior vice president and chief financial officer, effective April 2, 2009. Mr. Conroy is joining the company’s board of directors immediately.[More...]